+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

China Pharma Holdings Inc (CPHI) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 40 Pages
  • October 2024
  • Region: China
  • GlobalData
  • ID: 4337685
China Pharma Holdings Inc (CPHI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

China Pharma Holdings Inc (China Pharma) develops, manufactures, and markets pharmaceutical products for human use, targeting high-incidence and high-mortality diseases. The company’s product portfolio includes dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The company offers western and traditional Chinese medicines in different therapeutic areas including central nervous system (CNS), cardiovascular, cerebrovascular, anti-viral, digestive diseases, infectious diseases, food supplements and others. China Pharma offers products in various dosage forms including lyophilized injectables, granules, tablets, capsules, injectables and oral fluids. It markets products in various provinces through sales offices across China. China Pharma is headquartered in Haikou, Hainan, China.

China Pharma Holdings Inc Key Recent Developments

  • Nov 29, 2023: China Pharma Holdings Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • China Pharma Holdings Inc - Key Facts
  • China Pharma Holdings Inc - Key Employees
  • China Pharma Holdings Inc - Key Employee Biographies
  • China Pharma Holdings Inc - Major Products and Services
  • China Pharma Holdings Inc - History
  • China Pharma Holdings Inc - Company Statement
  • China Pharma Holdings Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • China Pharma Holdings Inc - Business Description
  • Product Category: Anti-Viral/ Infection & Respiratory
  • Overview
  • Performance
  • Product Category: CNS Cerebral & Cardio Vascular
  • Overview
  • Performance
  • Product Category: Digestive Diseases
  • Overview
  • Performance
  • Product Category: Other
  • Overview
  • Performance
  • R&D Overview
  • China Pharma Holdings Inc - Corporate Strategy
  • China Pharma Holdings Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • China Pharma Holdings Inc - Strengths
  • China Pharma Holdings Inc - Weaknesses
  • China Pharma Holdings Inc - Opportunities
  • China Pharma Holdings Inc - Threats
  • China Pharma Holdings Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • China Pharma Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • China Pharma Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • China Pharma Holdings Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Nov 29, 2023: China Pharma Holdings Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • China Pharma Holdings Inc, Key Facts
  • China Pharma Holdings Inc, Key Employees
  • China Pharma Holdings Inc, Key Employee Biographies
  • China Pharma Holdings Inc, Major Products and Services
  • China Pharma Holdings Inc, History
  • China Pharma Holdings Inc, Subsidiaries
  • China Pharma Holdings Inc, Key Competitors
  • China Pharma Holdings Inc, Ratios based on current share price
  • China Pharma Holdings Inc, Annual Ratios
  • China Pharma Holdings Inc, Interim Ratios
  • China Pharma Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • China Pharma Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • China Pharma Holdings Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • China Pharma Holdings Inc, Performance Chart (2019 - 2023)
  • China Pharma Holdings Inc, Ratio Charts
  • China Pharma Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • China Pharma Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Chugai Pharmaceutical Co Ltd
  • Otsuka Holdings Co Ltd
  • Shanghai Junshi Biosciences Co Ltd
  • BrightGene Bio-Medical Technology Co Ltd
  • Shanghai Roche Pharmaceutical Co Ltd
  • China Nuokang Bio-Pharmaceutical Inc
  • China Meheco Topfond Pharma Co Ltd